BeiGene | Taiwan

Author Profile 

• Orcid
• scopus
• Researchgate

Early Academic Pursuits

His academic journey began at the National Cheng Kung University (NCKU) in Taiwan, where he earned his Bachelor’s degree in Chemical Engineering (1999-2003) and later a Master’s degree in Biochemistry and Molecular Biology (2003-2005). His thirst for knowledge and research led him to the University of Cologne in Germany, where he completed his Ph.D. in Biochemistry with magna cum laude honors (2008-2012). During his doctoral studies, Chi was awarded the prestigious fellowship from the Graduate School for Biological Sciences, marking the beginning of a distinguished academic career. Following his Ph.D., he undertook a postdoctoral fellowship at the University of Cologne in 2013, further honing his research skills and laying the groundwork for his future endeavors in cell therapy and bioprocess development.

 

Professional Endeavors

His professional career is marked by significant contributions to the field of cell therapy and bioprocess development. His extensive experience spans multiple high-profile roles in leading biopharmaceutical companies. At BeiGene, Ltd., where he currently serves as the Director of Cell Therapy CMC, Chi has played a crucial role in cell therapy research development and manufacturing. His responsibilities include evaluating cell therapy portfolios, establishing CMC strategies for IND and clinical phase I material production, and managing a development team focused on T cell processing, analytical science, quality control, and cGMP manufacturing.

 

Contributions and Research Focus on Biotech

His research focus spans cell therapy, bioprocess development, and cGMP manufacturing. His core expertise includes biologics/ cell therapy CMC management, asset technical evaluation, project management, drug substance/product process development, and IND-enabling activities. His contributions to cell therapy research and bioprocess technology have been instrumental in bridging knowledge among process scales and phase-appropriate requirements, ensuring efficient delivery and high-performance outcomes.

He has led multiple biologics CMC projects, involving rigorous due diligence, proof of concept (POC) in continuous manufacturing processes, and implementation of process analytical technology. His leadership has been recognized in high-impact publications, including studies on continuous multi-column capture for monoclonal antibodies and the molecular mechanisms of nitrate reductase inhibition.

Accolades and Recognition

His achievements have earned him several honors and awards. He has been an invited speaker at prestigious conferences, such as the NMPAIED in 2022 and the Chinese Chemical Society in 2018. His leadership skills were also evident during his tenure as the Chairman of the Taiwanese Students’ Union in Cologne (2010-2011). His research excellence has been highlighted through a Ph.D. fellowship at the University of Cologne and notable publications in high-impact journals like the Journal of Biological Chemistry and Biochemistry.

Impact and Influence

His work has significantly impacted the biopharmaceutical industry, particularly in the areas of cell therapy and bioprocess development. His contributions have enhanced the efficiency of drug substance production, ensured regulatory compliance, and facilitated the successful delivery of clinical trial materials. His innovative approach to combining scientific research with manufacturing technical operations has set new standards in the industry, fostering cross-functional cooperation and driving advancements in cell therapy and bioprocess technology.

Legacy and Future Contributions